IKEDA Hiroaki

J-GLOBAL         Last updated: Aug 2, 2019 at 11:06
 
Avatar
Name
IKEDA Hiroaki
Affiliation
Nagasaki University
Section
Graduate School of Medicine
Job title
associate professor
Degree
Doctor of Philosophy(Nagasaki University)

Research Areas

 
 

Academic & Professional Experience

 
Apr 2016
 - 
Today
Professor, Department of Oncology Graduate School of Biomedical Sciences, Nagasaki University
 
Jan 2015
 - 
Mar 2016
Professor, Mie University Graduate School of Medicine Department of immune-Gene Therapy
 
May 2009
 - 
Dec 2014
Associate Professor, Mie University Graduate School of Medicine
 
Sep 2006
 - 
Apr 2009
associate professor, Mie University Graduate School of Medicine
 
1999
 - 
2004
Research Associate, School of Medicine, Washington Univ.
 
1996
 - 
1999
Dept. of Internal Medicine, School of Medicine, Mie Univ.
 
1992
 - 
1992
Medical intern, Dept. of Internal Medicine, School of Medicine, Nagasaki Univ.
 
1991
 - 
1992
Medical intern, Sasebo City General Hospital
 
1990
 - 
1991
Medical intern, Dept. of Internal Medicine, School of Medicine, Nagasaki Univ.
 

Education

 
 
 - 
1996
Graduate School, Division of Medicine, Nagasaki University
 
 
 - 
1983
Faculty of Medicine, Nagasaki University
 

Published Papers

 
Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma.
Kakimoto T, Matsumine A, Kageyama S, Asanuma K, Matsubara T, Nakamura T, Iino T, Ikeda H, Shiku H, Sudo A.
Oncol Lett   17(4) 3937-3943   Apr 2019   [Refereed]
Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance.
Muraoka D, Seo N, Hayashi T, Tahara Y, Fujii K, Tawara I, Miyahara Y, Okamori K, Yagita H, Imoto S, Yamaguchi R, Komura M, Miyano S, Goto M, Sawada SI, Asai A, Ikeda H, Akiyoshi K, Harada N, Shiku H.
J Clin Invest.   129(3) 1278-1294   Mar 2019   [Refereed]
NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma.
Ueda S, Miyahara Y, Nagata Y, Sato E, Shiraishi T, Harada N, Ikeda H, Shiku H, Kageyama S.
Oncotarget.   9(89) 35997-36011   Nov 2018   [Refereed]
Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination.
Akahori Y, Wang L, Yoneyama M, Seo N, Okumura S, Miyahara Y, Amaishi Y, Okamoto S, Mineno J, Ikeda H, Maki T, Fujiwara H, Akatsuka Y, Kato T, Shiku H.
Blood   132(11) 1134-1145   Sep 2018   [Refereed]
Prognostic value of MAGEA4 in primary lung cancer depends on subcellular localization and p53 status.
Fujiwara-Kuroda A, Kato T, Abiko T, Tsuchikawa T, Kyogoku N, Ichinokawa M, Tanaka K, Noji T, Hida Y, Kaga K, Matsui Y, Ikeda H, Kageyama S, Shiku H, Hirano S.
Int J Oncol.   53(2) 713-724   Aug 2018   [Refereed]

Misc

 
T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
IKEDA Hiroaki
Int Immunol.   28(7) 349-353   Jul 2016   [Refereed]
[Immunotherapy of solid tumor: perspectives on vaccine and cell therapy].
Ikeda H, Shiku H
Nihon rinsho. Japanese journal of clinical medicine   70(12) 2043-2050   Dec 2012   [Refereed]
[Targeting cancer antigen (MAGE-A4, NY-ESO -1) for immunotherapy].
Imai N, Ikeda H, Shiku H
Nihon rinsho. Japanese journal of clinical medicine   70(12) 2125-2129   Dec 2012   [Refereed]
Ikeda H
Immunotherapy   4(3) 241-244   Mar 2012   [Refereed]
Ikeda H, Shiku H
Advances in experimental medicine and biology   746 202-215   2012   [Refereed]

Conference Activities & Talks

 
Adoptive cell therapy with gene-engineered T cells for cancer patients
15 Apr 2019   

Research Grants & Projects

 
Development of adoptive T cell therapy of cancer and cancer vaccine, analysis of cancer immunoediting